Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shot up 10.5% during mid-day trading on Monday . The stock traded as high as $2.35 and last traded at $2.10, with a volume of 3,167,164 shares. The stock had previously closed at $1.90.

Several research firms have issued reports on CNAT. Brean Capital reaffirmed a “buy” rating and set a $7.00 price target (down from $13.00) on shares of Conatus Pharmaceuticals in a research note on Monday, May 9th. FBR & Co reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Sunday, May 8th. Roth Capital began coverage on shares of Conatus Pharmaceuticals in a research note on Friday, July 1st. They set a “buy” rating on the stock. Finally, Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Wednesday, August 10th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $9.41.

The firm’s market cap is $41.50 million. The company’s 50-day moving average is $2.10 and its 200-day moving average is $2.24.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.08. During the same period in the previous year, the firm posted ($0.31) earnings per share. Equities research analysts expect that Conatus Pharmaceuticals Inc. will post ($1.34) EPS for the current fiscal year.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.